Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 2900 of 3499 entries
View as:

Campath-1H and EPOCH to Treat Non-Hodgkin's T- and NK-Cell Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT00069238 Org: User:
Start: 09/19/03 End: 03/17/21 Due: 03/17/22

EPOCH Chemotherapy +/- IL-12 for Previously Untreated and EPOCH Plus Rituximab for Previously Treated Patients With AIDS-Associated Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00001563 Org: User:
Start: 01/08/97 End: 05/05/05 Due: 05/05/06

MR Image Guided Therapy in Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01377753 Org: User:
Start: 08/12/11 End: 07/31/18 Due: 07/31/19

PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00028587 Org: User:
Start: 12/31/01 End: - Due: -

Premenopausal Hormone Concentrations in a Population of Women at Very Low Risk of Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00860886 Org: User:
Start: 03/02/09 End: 04/09/20 Due: 04/09/21

Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis

Phase: N/A Priority: Normal
NCT ID: NCT01981551 Org: User:
Start: 10/31/13 End: 12/01/23 Due: 12/01/24

Prospective Randomized Comparative Study of Cell Transfer Therapy Using CD8+-Enriched Short-Term Cultured Anti-Tumor Autologous Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Compared to High-Dose Aldesleukin in M...

Phase: N/A Priority: Normal
NCT ID: NCT01118091 Org: User:
Start: 04/30/10 End: 04/30/12 Due: 04/30/13

Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00016302 Org: User:
Start: 04/30/01 End: - Due: -

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

Phase: N/A Priority: Normal
NCT ID: NCT04294641 Org: User:
Start: 05/10/21 End: 06/28/26 Due: 06/28/27

Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01585805 Org: User:
Start: 05/15/12 End: 03/06/26 Due: 03/06/27

Satraplatin in Children and Young Adults With Refractory Solid Tumors Including Brain Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01259479 Org: User:
Start: 12/03/10 End: 05/29/15 Due: 05/29/16

Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01059786 Org: User:
Start: 07/01/10 End: 12/31/27 Due: 12/31/28

MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03300817 Org: User:
Start: 12/27/17 End: 12/01/25 Due: 12/01/26

Pirfenidone in Treating Patients With Fibrosis Caused by Radiation Therapy for Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00020631 Org: User:
Start: 10/31/01 End: 10/31/07 Due: 10/31/08

Cisplatin/Carboplatin and Etoposide With or Without Nivolumab in Treating Patients With Extensive Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03382561 Org: User:
Start: 05/02/18 End: 12/31/25 Due: 12/31/26

Feasibility Study of Interleukin 1-Alpha With Ifosfamide, CBDCA, and Etoposide With Autologous Bone Marrow Transplant in Metastatic Carcinoma and Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00001270 Org: User:
Start: 06/30/91 End: 03/31/00 Due: 03/31/01

Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01217450 Org: User:
Start: 10/31/12 End: 05/31/14 Due: 05/31/15

Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00281957 Org: User:
Start: 08/31/07 End: 01/31/11 Due: 01/31/12

Gefitinib in Treating Children With Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00040781 Org: User:
Start: 06/30/02 End: - Due: -

Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00072176 Org: User:
Start: 05/31/04 End: 08/31/09 Due: 08/31/10

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT01814046 Org: User:
Start: 03/01/13 End: 05/31/17 Due: 05/31/18

A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00064259 Org: User:
Start: 06/30/03 End: 02/28/10 Due: 02/28/11

Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00118248 Org: User:
Start: 12/31/04 End: 04/30/12 Due: 04/30/13

Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04929028 Org: User:
Start: 08/09/22 End: 09/15/29 Due: 09/15/30

Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.

Phase: N/A Priority: Normal
NCT ID: NCT00107432 Org: User:
Start: 10/31/04 End: - Due: -